Cite
HARVARD Citation
Reardon, D. et al. (n.d.). ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-oncology. p. vi10. [Online].